| Influenza virus resistance to neuraminidase inhibitors M Samson, A Pizzorno, Y Abed, G Boivin Antiviral research 98 (2), 174-185, 2013 | 416 | 2013 |
| Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates P Maisonnasse, J Guedj, V Contreras, S Behillil, C Solas, R Marlin, ... Nature 585 (7826), 584-587, 2020 | 395 | 2020 |
| Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia A Pizzorno, B Padey, T Julien, S Trouillet-Assant, A Traversier, ... Cell Reports Medicine 1 (4), 2020 | 251 | 2020 |
| Timing of antiviral treatment initiation is critical to reduce SARS‐CoV‐2 viral load A Gonçalves, J Bertrand, R Ke, E Comets, X De Lamballerie, D Malvy, ... CPT: pharmacometrics & systems pharmacology 9 (9), 509-514, 2020 | 228 | 2020 |
| Generation and characterization of recombinant pandemic influenza A (H1N1) viruses resistant to neuraminidase inhibitors A Pizzorno, X Bouhy, Y Abed, G Boivin Journal of Infectious Diseases 203 (1), 25-31, 2011 | 171 | 2011 |
| In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2 A Pizzorno, B Padey, J Dubois, T Julien, A Traversier, V Dulière, P Brun, ... Antiviral research 181, 104878, 2020 | 146 | 2020 |
| Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs J Lopez, M Mommert, W Mouton, A Pizzorno, K Brengel-Pesce, M Mezidi, ... Journal of Experimental Medicine 218 (10), e20211211, 2021 | 135 | 2021 |
| Drug repurposing approaches for the treatment of influenza viral infection: reviving old drugs to fight against a long-lived enemy A Pizzorno, B Padey, O Terrier, M Rosa-Calatrava Frontiers in immunology 10, 531, 2019 | 120 | 2019 |
| Influenza drug resistance A Pizzorno, Y Abed, G Boivin Seminars in respiratory and critical care medicine 32 (04), 409-422, 2011 | 113 | 2011 |
| Role of permissive neuraminidase mutations in influenza A/Brisbane/59/2007-like (H1N1) viruses Y Abed, A Pizzorno, X Bouhy, G Boivin PLoS pathogens 7 (12), e1002431, 2011 | 82 | 2011 |
| Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus A Pizzorno, Y Abed, X Bouhy, É Beaulieu, C Mallett, R Russell, G Boivin Antimicrobial agents and chemotherapy 56 (3), 1208-1214, 2012 | 78 | 2012 |
| Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia D Asarnow, B Wang, WH Lee, Y Hu, CW Huang, B Faust, PML Ng, ... Cell 184 (12), 3192-3204. e16, 2021 | 71 | 2021 |
| Autoantibodies against type I IFNs in patients with critical influenza pneumonia Q Zhang, A Pizzorno, L Miorin, P Bastard, A Gervais, T Le Voyer, L Bizien, ... Journal of Experimental Medicine 219 (11), e20220514, 2022 | 67 | 2022 |
| Impact of Potential Permissive Neuraminidase Mutations on Viral Fitness of the H275Y Oseltamivir-Resistant Influenza A(H1N1)pdm09 Virus In Vitro, in Mice and in … Y Abed, A Pizzorno, X Bouhy, C Rhéaume, G Boivin Journal of virology 88 (3), 1652-1658, 2014 | 60 | 2014 |
| Repurposing of drugs as novel influenza inhibitors from clinical gene expression infection signatures A Pizzorno, O Terrier, C Nicolas de Lamballerie, T Julien, B Padey, ... Frontiers in immunology 10, 60, 2019 | 53 | 2019 |
| Antiviral properties of the NSAID drug naproxen targeting the nucleoprotein of SARS-CoV-2 coronavirus O Terrier, S Dilly, A Pizzorno, D Chalupska, J Humpolickova, E Bouřa, ... Molecules 26 (9), 2593, 2021 | 44 | 2021 |
| SARS-CoV-2 viral dynamics in non-human primates A Gonçalves, P Maisonnasse, F Donati, M Albert, S Behillil, V Contreras, ... PLoS computational biology 17 (3), e1008785, 2021 | 43 | 2021 |
| The 2009 pandemic H1N1 D222G hemagglutinin mutation alters receptor specificity and increases virulence in mice but not in ferrets Y Abed, A Pizzorno, ME Hamelin, A Leung, P Joubert, C Couture, ... Journal of Infectious Diseases 204 (7), 1008-1016, 2011 | 42 | 2011 |
| Characterization of cellular transcriptomic signatures induced by different respiratory viruses in human reconstituted airway epithelia C Nicolas de Lamballerie, A Pizzorno, J Dubois, T Julien, B Padey, ... Scientific reports 9 (1), 11493, 2019 | 40 | 2019 |
| OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes J Del Campo, A Pizzorno, S Djebali, J Bouley, M Haller, J Pérez-Vargas, ... NPJ vaccines 4 (1), 4, 2019 | 40 | 2019 |
